The report titled Global PARP Inhibitor Market: Size, Trends and Forecasts (2016-2020) provides an in-depth analysis of the global PARP inhibitor market with detailed analysis of market size on the basis of value along with the comprehensive examination of each of the segments of the market, namely, Lynparza, Niraparib, Rucaparib, Talazoparib and Veliparib.
The report analyses the global Lynparza market in detail along with the regional analysis as it is the only commercialized product in the market. The clinical trials of Niraparib, Rucaparib, Talazoparib and Veliparib are also summarized along with the anticipated market commencement for each of the products.
The report provides detailed market potential of PARP inhibitor in Ovarian cancer, Breast cancer, Prostate cancer and Pancreatic cancer. This section provides the detailed analysis of the clinical trials of various PARP inhibitors for the concerned cancer treatment.
The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global PARP inhibitor market has also been forecasted for the period 2016-2020, taking into consideration the research & development, the growth drivers and the current and future trends. The competition in the global PARP inhibitor market is stiff and dominated by the big players like AstraZeneca. Further, key players in the market, AbbVie, Clovis Oncology, Medivation and Tesaro are also profiled with their financial information and respective business strategies.
Get The Sample Copy Of Report : https://www.marketresearchreports.biz/sample/sample/866444
Clovis Oncology, Inc.
The global PARP inhibitor market has flourished since 2015 as in late 2014, the first PARP inhibitor product was launched and projections are made that the market would rise in the next five years i.e. 2016-2020 tremendously. The market is spread across the globe with the United States and Europe dominating the market.
The PARP inhibitor market can be segmented on the basis of the products into Lynparza, Niraparib, Rucaparib, Talazoparib and Veliparib. Currently, Lynparza is the only commercialized product in the market while other four products are in the development/trial stage. The market for Veliparib is expected to flourish since 2017 while the markets for Niraparib, Rucaparib and Talazoparib is expected to commence from 2018.
The major growth drivers for the global PARP inhibitor market are: rise in cancer incidences and PARP inhibitors in clinical routine. Despite the market is governed by growth drivers, there are certain challenges faced by the market such as: side-effects of PARP inhibitors and resistance to PARP inhibition. Some of the recent and major trends in the market include, various PARP inhibitors in the pipeline, inhibiting enzyme versus PARP trapping, the combination of PARP inhibitor & c-MET and pill burden likely to decline in the near future.
1. Executive Summary
2.1 DNA Damage Response (DDR)
2.2 DNA Damage Response (DDR) Drug Portfolio
2.3 PARP Inhibitor
2.3.1 Introduction to PARP Inhibitor
2.3.2 Inhibiting PARP Mechanism
2.3.3 PARP Inhibitor as a Cancer Treatment
2.3.4 PARP Inhibitor Development
3. Global Market Analysis
3.1 Global PARP Inhibitor Market by Value
3.2 Global PARP Inhibitor Market by Segments
3.2.1 Global Lynparza Market Analysis
Ongoing Lynparza Trials
Global Lynparza Market by Value
Global Lynparza Market by Region
3.2.2 Global Niraparib Market Analysis
Ongoing Niraparib Trials
Global Niraparib Market by Value
3.2.3 Global Rucaparib Market Analysis
Ongoing Rucaparib Trials
Global Rucaparib Market by Value
3.2.4 Global Talazoparib Market Analysis
Ongoing Talazoparib Trials
Global Talazoparib Market by Value
3.2.5 Global Veliparib Market Analysis
Ongoing Veliparib Trials
Global Veliparib Market by Value
4. Global PARP Inhibitor Market Potential Analysis
4.1 Global PARP Inhibitor Market Potential
4.2 Global Ovarian Cancer Market Opportunity
4.3 Global Breast Cancer Market Opportunity
4.4 Global Prostate Cancer Market Opportunity
4.5 Global Pancreatic Market Opportunity
5. Market Dynamics
5.1 Growth Drivers
5.1.1 Rise in Cancer Incidences
5.1.2 PARP Inhibitors in Clinical Routine
5.2.1 PARP Inhibitors Side-Effects
5.2.2 Resistance to PARP Inhibition
5.3 Market Trends
5.3.1 PARP Inhibitors in Pipeline
5.3.2 Inhibiting Enzyme and PARP Trapping
5.3.3 Combination of PARP Inhibitors and c-MET
5.3.4 PARP Inhibitor Pill Burden
6. Competitive Landscape
7. Company Profiling
7.1 AstraZeneca PLC
7.1.1 Business Overview
7.1.2 Financial Overview
7.1.3 Business Strategy
7.2 AbbVie Inc.
7.2.1 Business Overview
7.2.2 Financial Overview
7.2.3 Business Strategy
7.3 Clovis Oncology, Inc.
7.3.1 Business Overview
7.3.2 Financial Overview
7.3.3 Business Strategy
Request To Buy This Report : https://www.researchmoz.com/checkout?rep_id=866444&licType=S
7.4 Medivation, Inc.
7.4.1 Business Overview
7.4.2 Financial Overview
7.4.3 Business Strategy
7.5 Tesaro, Inc.
7.5.1 Business Overview
7.5.2 Financial Overview
7.5.3 Business Strategy
Company Name: MarketResearchReports.Biz
Contact Person: Rohit Bhisey
Email: Send Email
Address:State Tower 90 State Street, Suite 700
State: NY 12207
Country: United States